Beam Therapeutics Inc. (BEAM)
NASDAQ · Healthcare
Beam Therapeutics Inc. EBITDA 2019–2025
Beam Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2019 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Beam Therapeutics Inc. ebitda for the quarter ending March 31, 2026 was -101.6 M, a 10.68% decrease year-over-year.
- Beam Therapeutics Inc. ebitda for the twelve months ending March 31, 2026 was -451.2 M, a 14.72% increase year-over-year.
- Beam Therapeutics Inc. annual ebitda for 2025 was -361.4 M, a 8.19% decrease from 2024.
- Beam Therapeutics Inc. annual ebitda for 2024 was -393.6 M, a 151.57% increase from 2023.
- Beam Therapeutics Inc. annual ebitda for 2023 was -156.5 M, a 51.76% decrease from 2022.
- Beam Therapeutics Inc. annual ebitda for 2022 was -324.3 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Beam Therapeutics Inc. EBITDA — FAQ
Beam Therapeutics Inc. (BEAM) ebitda over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see BEAM's ebitda history?
The chart and table above show Beam Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.